Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis

Burke, Thomas F.; Villanueva, Catalina; Mariano, H.G.; Huck, W; Orchard, Douglas; Haverstock, Daniel; Heyd, Allen; Church, D.

doi:10.1016/s0149-2918(99)80046-0

Cited by 56 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two additional trials eligible for inclusion were detected after a secondary search on the Scopus database, but no additional trials were identified in the Cochrane Central Register of Controlled Trials. A total of 11 trials [21][22][23][24][25][26][27][28][29][30][31] were included in the meta-analysis ( Figure 1). The 2 reviewers independently reached the same conclusions regarding studies to be included.…”

Section: Selected Trialsmentioning

confidence: 99%

“…In addition to the treatments being compared in these studies, adjunctive medications for symptomatic relief, mostly decongestants, antihistamines and analgesics, were permitted in 8 of the trials. 22,[24][25][26][27][28][29][30] Two of these trials reported the percentage of patients using such medications: 76% in one study 28 and 83.5% in the other.…”

Section: Characteristics Of the Selected Trialsmentioning

confidence: 99%

“…Adequate randomization procedures were reported in 6 of the 11 trials, 22,23,24,[28][29][30] allocation concealment was reported in 3 trials, 22,24,31 masking of the intervention was reported in 5 trials, 22,24,26,28,29 information on patient withdrawals from the trials was reported in 7 trials, 22,25-30 crossovers of patients between treatment arms were reported in 1 trial, 27 and violation of the inclusion criteria was reported in 4 trials. 26,28,29,31 In 10 of the 11 trials, the fluoroquinolone was the experimental treatment and the β-lactam antibiotic the comparator; in the other trial, the fluoroquinolone (levofloxacin) served as CMAJ • March 25, 2008 • 178 (7) 8 84 47 7…”

mentioning

confidence: 99%

“…26,28,29,31 In 10 of the 11 trials, the fluoroquinolone was the experimental treatment and the β-lactam antibiotic the comparator; in the other trial, the fluoroquinolone (levofloxacin) served as CMAJ • March 25, 2008 • 178 (7) 8 84 47 7…”

mentioning

confidence: 99%

See 3 more Smart Citations

Fluoroquinolones compared with -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

Karageorgopoulos¹,

Giannopoulou²,

Grammatikos³

et al. 2008

Canadian Medical Association Journal

View full text Add to dashboard Cite

Section: Selected Trialsmentioning

confidence: 99%

Section: Characteristics Of the Selected Trialsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Fluoroquinolones compared with -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

Karageorgopoulos¹,

Giannopoulou²,

Grammatikos³

et al. 2008

Canadian Medical Association Journal

View full text Add to dashboard Cite

“…L'efficacia clinica e la tollerabilità della moxifloxacina nella CAP, nelle AECB e nelle ABS sono state studiate su un numero elevato di pazienti, nel corso di diversi trial multicentrici controllati, nazionali e internazionali, strutturati nella maggior parte come studi in doppio cieco [101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118].…”

Section: Efficacia Clinica E Batteriologica Nelle Infezioni Acute Delunclassified

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Eandi

2003

View full text Add to dashboard Cite

PREMESSEMoxifloxacina è un nuovo fluorochinolone di recente introduzione nell'armamentario terapeutico per il trattamento antibiotico delle infezioni delle basse ed alte vie respiratorie [1][2][3][4][5][6][7].Moxifloxacina è un 8-metossichinolone dotato di un ampio spettro d'azione antibatterico nei confronti dei batteri Grampositivi e Gram-negativi, aerobi ed anaerobi e dei patogeni atipici quali micoplasmi, legionelle e clamidie [3, 7, 8]. Questo nuovo antibiotico è tra i farmaci più potenti attualmente disponibili nei confronti dei batteri Gram-positivi, compresi lo Staphylococcus aureus meticillino-resistente e i pneumococchi, sia sensibili che resistenti alla penicillina. La moxifloxacina è attiva quanto la ciprofloxacina verso Legionella spp., ma più attiva verso Chlamydia spp. e Mycoplasma pneumoniae. Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomicoMario Eandi * Moxifloxacina manifesta minore efficacia rispetto a ciprofloxacina verso le Enterobatteriaceae e verso Pseudomonas aeruginosa. Dotata di una potente e rapida azione battericida concentrazione-dipendente verso i batteri Gram-positivi e di un marcato effetto post-antibiotico, la moxifloxacina si accumula rapidamente nei ceppi sensibili, agisce inibendo in ugual misura sia la DNA girasi sia la topoisomerasi IV e manifesta una ridotta tendenza a selezionare ceppi mutanti resistenti [1, 7].La farmacocinetica della moxifloxacina si caratterizza per la lunga emivita, circa 12 ore, per un'elevata biodisponibilità orale, un'eccellente diffusibilità tissutale extravascolare e per la scarsità di interazioni con altri farmaci [1, 7]. Il profilo di tollerabilità, simile a quello dei fluorochinoloni, si differenzia, tuttavia, per l'assenza di fototossicità [2]. ABSTRACTMoxifloxacin is a new fluorquinolone antibiotic, recently introduced among the treatment options for upper and lower airways infections. It possesses a wide antibiotic spectrum, covering the major pathogens involved in the genesis of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS). It acts in a concentration-dependent manner by inhibition of bacterial DNAgirase and topoisomerase IV, has a long biological half-life (about 12 hours), good oral bioavailability, excellent tissue diffusion and a better safety profile than other quinolones, because of the lack of phototoxicity and the scarsity of clinically significant drug interactions. The clinical results of moxifloxacin in CAP, AECB and ABS have been compared with those of available alternative antibiotics in several multicentric, double-blind studies, and the new fluorquinolone resulted at least as effective as the comparators, with similar tolerability profiles. These studies demonstrated a high correlation among the eradication of the pathogen and the clinical recovery of the patients. The pharmacodynamics, pharmacokinetics and clinical results of moxifloxacin render it one of the most attractive options for the empirical treatment of upper and lower air...

show abstract

Impact of First-Line vs Second-Line Antibiotics for the Treatment of Acute Uncomplicated Sinusitis

Piccirillo

Mager²,

Frisse³

et al. 2001

JAMA

View full text Add to dashboard Cite

show abstract

Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis

Cited by 56 publications

References 13 publications

Fluoroquinolones compared with -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

Fluoroquinolones compared with -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Impact of First-Line vs Second-Line Antibiotics for the Treatment of Acute Uncomplicated Sinusitis

Contact Info

Product

Resources

About